Infliximab vs placebo: Clinical relapse
- Population
- patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
- Intervention
- Infliximab
- Comparison
- placebo
- Outcome
- Clinical relapse
Infliximab probably leads to lower clinical relapse (at 30‐32 weeks, CDAI > 150) compared with placebo (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Infliximab vs placebo Clinical relapse (at 30‐32 weeks, CDAI > 150) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline) Infliximab probably leads to lower clinical relapse (at 30‐32 weeks, CDAI > 150) compared with placebo (moderate certainty). Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane Headline outcomes only | RR 0.73 [0.63, 0.84] | 2 studies · 408 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Infliximab vs adalimumab · patients with Crohn's disease (active disease population with clinical response at… · 1 review
- Infliximab vs biosimilar · patients with Crohn's disease (with mixed/low disease activity at baseline) · 1 review
- Infliximab vs purine analogues · Participants with Crohn's disease in remission · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.